Synapse - Department of Medicine

Results (39721)

FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)

Meeting Abstract

Nguyen, P. L.; Kollmeier, M.; Rathkopf, D. E.; Hoffman, K. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)

Meeting Abstract

Aggarwal, R. R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer

Meeting Abstract

Zaidi, S.; Chan, J. M.; Love, J.; Zhao, J.; Setty, M.; Lawrence, K.; Gopalan, A.; Goodrich, D.; Morris, M. J.; Chen, Y.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Barriers to guideline-concordant use of bone modifying agents for prostate cancer

Meeting Abstract

Mitchell, A. P.; Persaud, S.; Chimonas, S.; Salner, A. L.; Palyca, P.; Farooki, A.; Ostroff, J. S.; Morris, M. J.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer

Meeting Abstract

Mucci, L. A.; Vinson, J.; Gerke, T. A.; Hyslop, T.; Howard, L.; Dreicer, R.; Rathkopf, D. E.; Chi, K. N.; Esteban, E.; Enting, D.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer

Meeting Abstract

Morris, M. J.; Linch, M. D.; Crabb, S. J.; Beer, T. M.; Heath, E. I.; Gordon, M. S.; De Bono, J. S.; Pashova, H. I.; Tudor, I. C.; Greenstein, A. E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE

Meeting Abstract

Efstathiou, E.; Smith, M. R.; Sandhu, S.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Gomes, A. J.; Small, E. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Meeting Abstract

Castro, E.; Chi, K. N.; Sandhu, S.; Olmos, D.; Attard, G.; Saad, M.; Gomes, A. J.; Rathkopf, D. E.; Smith, M. R.; Kang, T. W.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy

Meeting Abstract

Bryce, A. H.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; McDermott, R. S.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Abida, W.; Daugaard, G.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Changes in planned disease management after piflufolastat F(18) PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study

Meeting Abstract

Pouliot, F.; Gorin, M. A.; Rowe, S. P.; Saperstein, L.; Denes, B. S.; DiPippo, V. A.; Stambler, N.; Morris, M. J.; Siegel, B. A.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save